U.S. Markets closed
  • S&P 500

    3,900.11
    -11.63 (-0.30%)
     
  • Dow 30

    31,438.26
    -62.42 (-0.20%)
     
  • Nasdaq

    11,524.55
    -83.07 (-0.72%)
     
  • Russell 2000

    1,771.74
    +6.01 (+0.34%)
     
  • Crude Oil

    109.89
    +0.32 (+0.29%)
     
  • Gold

    1,823.10
    -1.70 (-0.09%)
     
  • Silver

    21.16
    -0.01 (-0.04%)
     
  • EUR/USD

    1.0585
    +0.0027 (+0.2540%)
     
  • 10-Yr Bond

    3.1940
    +0.0690 (+2.21%)
     
  • Vix

    26.95
    -0.28 (-1.03%)
     
  • GBP/USD

    1.2267
    -0.0003 (-0.0245%)
     
  • USD/JPY

    135.3790
    +0.2090 (+0.1546%)
     
  • BTC-USD

    20,884.66
    -389.96 (-1.83%)
     
  • CMC Crypto 200

    455.80
    -6.00 (-1.30%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Recap: OraSure Technologies Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of OraSure Technologies (NASDAQ:OSUR) fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 50.00% over the past year to $0.03, which missed the estimate of $0.07.

Revenue of $62,855,000 higher by 26.55% year over year, which beat the estimate of $57,290,000.

Looking Ahead

OraSure Sees Q1 Net Sales $55M-$60M

Conference Call Details

Date: Mar 01, 2021

Time: 05:00 PM

View more earnings on OSUR

ET Webcast URL: https://edge.media-server.com/mmc/p/95z6s52d

Technicals

Company's 52-week high was at $19.75

Company's 52-week low was at $5.23

Price action over last quarter: down 13.77%

Company Description

OraSure Technologies Inc is engaged in the development, manufacturing, and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its reportable segments are OSUR and DNAG. The OSUR business, consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices, DNAG segment manufacture and sell kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. It generates a majority of its revenue from the OSUR business segment.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.